These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37650770)

  • 1. Toxic epidermal necrolysis post apalutamide with preceding tislelizumab administration in a patient with two cancers.
    Wu W; Da M; Chen M; Wang F; Wu Y; Du Y; Sun L; Zhu X; Wang F
    J Dtsch Dermatol Ges; 2023 Oct; 21(10):1221-1223. PubMed ID: 37650770
    [No Abstract]   [Full Text] [Related]  

  • 2. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
    Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
    Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction.
    Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L
    Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146
    [No Abstract]   [Full Text] [Related]  

  • 4. Tislelizumab-Induced Toxic Epidermal Necrolysis-Like Cutaneous Adverse Reaction: Rare Complication of Immune Checkpoint Inhibitor Therapy.
    Yang X; Xu S
    Am J Ther; 2024 Jul-Aug 01; 31(4):e470-e474. PubMed ID: 38976533
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome.
    Lazaridou I; Calvani J; Annabi E; Moins-Teisserenc H; Ta VA; Rivet J; Ram-Wolff C; Dumont M; Mahevas T; Vignon-Pennamen MD; Mourah S; Bouaziz JD; Louveau B; Bagot M; Battistella M; de Masson A
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e715-e717. PubMed ID: 36645855
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome/toxic epidermal necrolysis related to apalutamide.
    Hsu YO; Hsieh TS; Huang PW; Chu CY
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e246-e248. PubMed ID: 36223304
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Ziemer CM; Miedema J; Smith CJ; Liu Z; Thomas NE; Googe PB
    Am J Dermatopathol; 2021 Apr; 43(4):318-320. PubMed ID: 33055536
    [No Abstract]   [Full Text] [Related]  

  • 11. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
    Tanba K; Uoshima N; Uchiyama H; Kawata E; Isa R; Yamaguchi J; Tsutsumi Y; Akaogi T; Kobayashi Y; Katsura K; Kuroda J; Taniwaki M
    Ann Hematol; 2016 Mar; 95(4):661-2. PubMed ID: 26754634
    [No Abstract]   [Full Text] [Related]  

  • 12. Absence of toxic epidermal necrolysis recurrence with pembrolizumab re-challenge in a patient with a positive lymphocyte transformation test.
    Kawada M; Nobeyama Y; Goto Y; Nakama K; Yamazaki N; Asahina A
    J Dermatol; 2020 Dec; 47(12):e424-e425. PubMed ID: 32815211
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal case of toxic epidermal necrolysis due to apalutamide used as a novel prostate cancer drug.
    Endo Y; Oka A; Uehara A; Toki S; Motegi SI; Ishikawa O; Miyazawa Y; Suzuki K
    J Dermatol; 2020 Oct; 47(10):e359-e360. PubMed ID: 32662533
    [No Abstract]   [Full Text] [Related]  

  • 14. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.
    Lomax AJ; McQuillan PIA; Hall A; McArthur GA
    Intern Med J; 2019 Aug; 49(8):1051-1053. PubMed ID: 31387152
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic Epidermal Necrolysis Caused by Apalutamide: A Case Report of Treatment Using Etanercept with Conventional Steroid Therapy.
    Osawa K; Kiniwa Y; Shimosato Y; Midorikawa H; Shirai T; Sano T; Nakamura K; Okuyama R
    Acta Derm Venereol; 2022 May; 102():adv00723. PubMed ID: 35578821
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
    Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
    Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.